HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI Meeting Abstract
| Authors: | Mok, T. S. K.; Wu, Y. L.; Nishio, M.; Reck, M.; Wu, E.; Sternberg, D. W.; Esker, S.; Yu, H. A. |
| Abstract Title: | HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1095 |
| Language: | English |
| ACCESSION: | WOS:000866211601457 |
| DOI: | 10.1016/j.annonc.2022.07.1318 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1195TiP -- Source: Wos |
